Skip Ribbon Commands
Skip to main content
Sign In

26589 Lyme Disease, Molecular Detection, PCR, Varies (LYMPV)

Lyme Disease, Molecular Detection, PCR, Varies (LYMPV)
Test Code: MISC
Synonyms/Keywords

​Borrelia afzelii; Borrelia burgdorferi by PCR; Borrelia burgdorferi sensu lato genogroup; Borrelia garini;

Borrelia mayonii; Lyme Disease; Lyme Disease (PCR); Lyme Disease,CSF; PCR; Sensu lato group; Spirochetes; Tick-Borne Diseases

Test Components

Previous serology positivity for Borrelia burgdorferi, is a requirement to order this test.
All CSF and synovial fluid specimens MUST be approved by Dr. Taylor Wahlig or Dr. Sophie Arbefeville prior to sending to Mayo Clinic Labs.

B. burgdorferi PCR, B. mayonii PCR, B. garinii/B. afzelii PCR

Useful For

Supporting the diagnosis of Lyme disease in conjunction with serologic testing

Specific indications including testing skin biopsies when a rash lesion is not characteristic of erythema migrans and testing synovial fluid or synovium to support the diagnosis of Lyme arthritis

This test should not be used to screen asymptomatic patients.

Specimen Requirements
Specimen Type
Preferred Container/TubeAcceptable Container/TubeSpecimen VolumeSpecimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
​CSF
​Sterile vial/container

​1 mL
​0.3 mL

​Synovial Fluid
​Sterile vial

​​1 mL
Collection Processing Instructions

Label specimen as CSF or synovial fluid

Specimen Stability Information
Specimen TypeTemperatureTime

Varies​

​Refrigerated (preferred)
​7 days
​Frozen
​7 days
Rejection Criteria

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Interference

​Serologic tests are recommended for diagnosis of Lyme disease. Polymerase chain reaction (PCR) may play an adjunctive role but may not detect Borrelia burgdorferi DNA from cerebrospinal fluid (CSF) in cases of active or chronic disease. The presence of inhibitory substances may also cause a false-negative result. If clinical features of illness are highly indicative of Lyme neuroborreliosis, serologic testing on CSF is warranted. PCR test results should be used as an aid in diagnosis and not considered diagnostic by themselves. These results should be correlated with serologic and epidemiologic data and clinical presentation of the patient.

Testing of CSF by PCR in patients with suspected Lyme neuroborreliosis should be requested only on patients with positive B burgdorferi antibody in serum confirmed by Western blot assay (LYWB / Lyme Disease Antibody, Immunoblot, Serum) and with abnormal CSF findings (elevated protein and WBC >10 cells/high-power field).

Concurrent infections with multiple tick-borne pathogens, including Ehrlichia muris eauclairensis, Anaplasma phagocytophilum, Babesia microti, and Borrelia miyamotoi (a relapsing fever Borrelia) have been reported in United States, and consideration should be given to testing for other pathogens, if clinically indicated.

This assay detects most members of the Borrelia burgdorferi sensu lato (Bbsl) complex, including Borrelia andersonii, Borrelia americana, and Borrelia bissettii, which have been rarely detected in humans. Detection of DNA from these organisms would be reported as an atypical result and prompt additional laboratory testing to further identify the DNA present. The sensitivity of this assay for detecting these organisms has not been determined.

This assay also detects some members of the Bbsl complex that are not considered to be human pathogens but may be found in ticks and other animals. Therefore, this assay should not be used to test nonhuman specimens.

Performing Laboratory Information
Performing LocationDay(s) Test PerformedReport Available
Methodology/Instrumentation

Mayo Clinic Laboratories​

June through November: Monday through Saturday

December through May: Monday through Friday

​Same day/ 1 to 4 days
​Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization
Reference Lab
Test Information

Lyme disease is a multisystem and multistage tick-transmitted infection caused by spirochetal bacteria in the Borrelia burgdorferi sensu lato (Bbsl) complex.(1) Nearly all human infections are caused by 3 Bbsl species; B burgdorferi sensu stricto (hereafter referred to as B burgdorferi) is the primary cause of Lyme disease in North America, while Borrelia afzelii and Borrelia garinii are the primary causes of Lyme disease in Europe. In 2012, Borrelia mayonii was identified as a less common cause of Lyme disease in the upper Midwestern United States.(2,3) This organism has only been detected in patients with exposure to ticks in Minnesota and Wisconsin and has not been detected in over 10,000 specimens from patients in other states, including regions of northeast where Lyme disease is endemic.

Lyme disease is the most commonly reported tick-borne infection in Europe and North America, causing an estimated 300,000 cases in the United States each year and 85,000 cases in Europe.(4,5) The clinical features of Lyme disease are broad and may be confused with various immune and inflammatory disorders. The classic presenting sign of early localized Lyme disease caused by B burgdorferi is erythema migrans (EM), which occurs in approximately 80% of individuals. Other early signs and symptoms include malaise, headache, fever, lymphadenopathy, and myalgia. Arthritis, neurological disease, and cardiac disease may be later stage manifestations. EM has also been seen in patients with B mayonii infection, but diffuse rashes are more commonly reported.(2) The chronic skin condition, acrodermatitis chronicum atrophicans, is also associated with B afzelii infection.

The presence of EM in the appropriate clinical setting is considered diagnostic for Lyme disease; no confirmatory laboratory testing is needed. In the absence of a characteristic EM lesion, serologic testing is the diagnostic method of choice for Lyme disease.(6) However, serology may not be positive until 1 to 2 weeks after onset of symptoms and may show decreased sensitivity for detection of infection with B mayonii. Therefore, detection of Bbsl DNA using polymerase chain reaction (PCR) may be a useful adjunct to serologic testing for detection of acute disease. PCR has shown utility for detection of Borrelia DNA from skin biopsies of Lyme-associated rashes and can be used to detect Borrelia DNA from synovial fluid and synovium biopsies. Less commonly, Borrelia DNA can be detected in cerebrospinal fluid.(7) Lyme PCR should always be performed in conjunction with US Food and Drug Administration-approved serologic tests, and the results should be correlated with serologic and epidemiologic data and clinical presentation of the patient.(8) The Mayo Clinic Lyme PCR test detects and differentiates the main causes of Lyme disease in North America (B burgdorferi and B mayonii) and Europe (B afzelii and B garinii).(2,7)

Reference Range Information

Negative

Reference values apply to all ages

Interpretation

A positive result indicates the presence of DNA from Borrelia burgdorferi, Borrelia mayonii, Borrelia afzelii, or Borrelia garinii, the main agents of Lyme disease.

A negative result indicates the absence of detectable target DNA in the specimen. Due to the clinical sensitivity limitations of the polymerase chain reaction assay, a negative result does not preclude the presence of the organism or active Lyme disease.

Synonyms/Keywords

​Borrelia afzelii; Borrelia burgdorferi by PCR; Borrelia burgdorferi sensu lato genogroup; Borrelia garini;

Borrelia mayonii; Lyme Disease; Lyme Disease (PCR); Lyme Disease,CSF; PCR; Sensu lato group; Spirochetes; Tick-Borne Diseases

Test Components

Previous serology positivity for Borrelia burgdorferi, is a requirement to order this test.
All CSF and synovial fluid specimens MUST be approved by Dr. Taylor Wahlig or Dr. Sophie Arbefeville prior to sending to Mayo Clinic Labs.

B. burgdorferi PCR, B. mayonii PCR, B. garinii/B. afzelii PCR

Ordering Applications
Ordering ApplicationDescription

​Cerner
​MISC

If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
Specimen Type
Preferred Container/TubeAcceptable Container/TubeSpecimen VolumeSpecimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
​CSF
​Sterile vial/container

​1 mL
​0.3 mL

​Synovial Fluid
​Sterile vial

​​1 mL
Collection Processing

Label specimen as CSF or synovial fluid

Specimen Stability Information
Specimen TypeTemperatureTime

Varies​

​Refrigerated (preferred)
​7 days
​Frozen
​7 days
Rejection Criteria

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Interference

​Serologic tests are recommended for diagnosis of Lyme disease. Polymerase chain reaction (PCR) may play an adjunctive role but may not detect Borrelia burgdorferi DNA from cerebrospinal fluid (CSF) in cases of active or chronic disease. The presence of inhibitory substances may also cause a false-negative result. If clinical features of illness are highly indicative of Lyme neuroborreliosis, serologic testing on CSF is warranted. PCR test results should be used as an aid in diagnosis and not considered diagnostic by themselves. These results should be correlated with serologic and epidemiologic data and clinical presentation of the patient.

Testing of CSF by PCR in patients with suspected Lyme neuroborreliosis should be requested only on patients with positive B burgdorferi antibody in serum confirmed by Western blot assay (LYWB / Lyme Disease Antibody, Immunoblot, Serum) and with abnormal CSF findings (elevated protein and WBC >10 cells/high-power field).

Concurrent infections with multiple tick-borne pathogens, including Ehrlichia muris eauclairensis, Anaplasma phagocytophilum, Babesia microti, and Borrelia miyamotoi (a relapsing fever Borrelia) have been reported in United States, and consideration should be given to testing for other pathogens, if clinically indicated.

This assay detects most members of the Borrelia burgdorferi sensu lato (Bbsl) complex, including Borrelia andersonii, Borrelia americana, and Borrelia bissettii, which have been rarely detected in humans. Detection of DNA from these organisms would be reported as an atypical result and prompt additional laboratory testing to further identify the DNA present. The sensitivity of this assay for detecting these organisms has not been determined.

This assay also detects some members of the Bbsl complex that are not considered to be human pathogens but may be found in ticks and other animals. Therefore, this assay should not be used to test nonhuman specimens.

Useful For

Supporting the diagnosis of Lyme disease in conjunction with serologic testing

Specific indications including testing skin biopsies when a rash lesion is not characteristic of erythema migrans and testing synovial fluid or synovium to support the diagnosis of Lyme arthritis

This test should not be used to screen asymptomatic patients.

Test Components

Previous serology positivity for Borrelia burgdorferi, is a requirement to order this test.
All CSF and synovial fluid specimens MUST be approved by Dr. Taylor Wahlig or Dr. Sophie Arbefeville prior to sending to Mayo Clinic Labs.

B. burgdorferi PCR, B. mayonii PCR, B. garinii/B. afzelii PCR

Reference Range Information

Negative

Reference values apply to all ages

Interpretation

A positive result indicates the presence of DNA from Borrelia burgdorferi, Borrelia mayonii, Borrelia afzelii, or Borrelia garinii, the main agents of Lyme disease.

A negative result indicates the absence of detectable target DNA in the specimen. Due to the clinical sensitivity limitations of the polymerase chain reaction assay, a negative result does not preclude the presence of the organism or active Lyme disease.

For more information visit:
Performing Laboratory Information
Performing LocationDay(s) Test PerformedReport Available
Methodology/Instrumentation

Mayo Clinic Laboratories​

June through November: Monday through Saturday

December through May: Monday through Friday

​Same day/ 1 to 4 days
​Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization
Reference Lab
For billing questions, see Contacts
For most current information refer to the Marshfield Laboratory online reference manual.